Precision Medicine in Psychiatric Drug Development: Opportunities and Challenges

1 Dr.S A Surale-Patil, 2 Dr.S.A.Jadhav, 3 Dr. Harsh K. Singh, 4 Dr.Vedant S. Patel,
5 Dr.Bharti Bhambhu,

1 Assistant Professor, Department of Pharmacology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University",Karad –415110, Maharashtra, Email: smitaasp73@gmail.com
2 Professor, Department of Pharmacology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed ToBe University",Karad –415110,
3 Tutor, Department of Pharmacology, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth "Deemed To Be University", Karad –415110, Maharashtra
4 Tutor, Department of Pharmacology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed To Be University", Karad –415110, Maharashtra
5 Tutor, Department of Pharmacology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth "Deemed To Be University", Karad –415110,Maharashtra

Abstract

Precision medicine, a new healthcare concept that tailors treatments to individuals, could revolutionize mental medication research. This review discusses precision medicine's mental health therapy pros and cons. Finding genetic variants linked to psychiatric disorders has helped researchers understand the molecular basis of major depressive disorder, bipolar disorder, and schizophrenia. Genetic markers emphasize the polygenicity of many diseases and enable targeted drug development by identifying therapeutic targets.

Pharmaceutical Genomics and Biomarkers: Biomarkers reveal disease progression, therapy efficacy, and side effects. Gene markers and neuroimaging indications. Pharmacogenomic methods predict therapeutic efficacy and side effects based on genetic differences. Biomarker-driven methods to clinical decision-making provide patient-specific treatment strategies.

Omics Technologies: Genomes, transcriptomics, proteomics, and metabolomics provide a complete biological understanding of mental diseases. These technologies help create targeted medicines by identifying therapeutic targets and disease markers.

Drug development and custom treatment: Personalized treatments that target biological processes connected to mental diseases are the focus of precision psychiatry. Biomarker-driven treatment techniques help categorize patients and identify therapies depending on their needs. This strategy streamlines pharmaceutical approval and improves clinical trial design by identifying patient categories likely to benefit from tailored therapy.

Standardsizing procedures, verifying biomarkers, and generating clinical utility recommendations are needed to implement these advancements into clinical practice. Ethical issues around patient privacy and fair access to personalized treatments also present challenges. Treatment heterogeneity and resistance Although personalized treatments have improved, some people still reject treatment, requiring further study of the causes. The heterogeneity of mental diseases requires highly tailored care.

Keywords: Precision Medicine, Psychiatric Disorders, Genetic Markers, Biomarkers, Pharmacogenomics

Introduction

With its goal of customizing medical procedures to each patient's unique traits, precision medicine has become a ground-breaking approach to healthcare that is altering treatment approaches in a variety of medical specialties. This paradigm change in psychiatry has the potential to improve treatment outcomes, especially in the area of developing medications to treat mental health illnesses. The study of individualized treatments in psychiatric care has been accelerated by the confluence of technology breakthroughs, particularly in the fields of genetics and data analytics. This approach presents a fresh way to address the heterogeneity and complexity of these disorders.

Psychiatric diseases represent a major worldwide health concern and range from sadness and anxiety to schizophrenia and bipolar disorder. Conventional treatment approaches have frequently used a one-size-fits-all strategy, prescribing drugs based on broad diagnostic categories and ignoring the subtle differences in each patient's reaction to medication. This restriction has led to high rates of treatment resistance, inadequate treatment efficaciousness, and an extended process of trial and error in determining the right drugs for patients.

To address these issues, Precision Medicine in Psychiatry aims to clarify the complex interactions among a person's genetic composition, surroundings, and particular biomarkers in order to customize treatment plans. Potential genetic markers linked to a range of psychiatric diseases have been found thanks to advancements in genetic research [1]. These markers provide information about the biological basis of these illnesses and have the potential to be used in tailored therapy development. They range from single nucleotide polymorphisms (SNPs) to copy number variations (CNVs) [2].

These genetic markers have a variety of effects on the creation of drugs. First of all, they aid in the discovery of new therapeutic targets by deepening our understanding of the molecular mechanisms connected to psychiatric diseases [3]. Second, by allowing patient populations to be stratified, these markers facilitate more specialized clinical trials and treatments that are catered to particular genetic groupings [4]. However, the polygenic nature of psychiatric diseases, the complexity of genetic interactions, and the requirement for strong validation in a range of patient cohorts present obstacles to the translation of these genetic results into therapeutically relevant insights [5].

Precision psychiatry has shown interest in biomarkers and pharmacogenomic techniques in addition to genetic indicators. Biomarkers provide possible indicators of therapy response, adverse pharmaceutical reactions, and disease progression, ranging from neuroimaging markers to peripheral biomarkers [6]. Contrarily, pharmacogenomics focuses on the interindividual heterogeneity in drug response brought on by genetic differences, which helps predict the effectiveness and side effects of drugs [7]. Optimizing treatment regimens and minimizing side effects can be achieved by incorporating these biomarkers and pharmacogenomic data into clinical decision-making processes.

The amalgamation of omics technologies, comprising transcriptomics, proteomics, metabolomics, and genomes, has enhanced our comprehension of the biological pathways that underlie mental illnesses [8]. Large volumes of data are produced by these high-throughput technologies, which calls for advanced data analytics and computational tools for interpretation. Personalized therapies may be guided by the capacity to examine multi-omics data and find treatment-responsive profiles or illness signatures. However, there are a number of standardization, data privacy, and ethical issues that present considerable barriers to the integration of different data sources and the validation of their therapeutic utility [9].

The incorporation of Precision Medicine into Psychiatric Drug Development signifies a paradigm change in the area and provides ways to overcome the drawbacks of traditional therapeutic modalities. Utilizing pharmacogenomics, biomarkers, genetic markers, and omics technology offers a chance to maximize treatment effectiveness, reduce side effects, and customize mental health care. However, there are still many obstacles to overcome before these developments may be implemented into standard clinical practice, calling for cross-disciplinary cooperation and careful confirmation of research results.

Psychiatric Disorders and Genetic Markers

Genetic markers are now important tools for navigating the complex terrain of mental illnesses. Our understanding of the underlying molecular mechanisms of disorders such as major depressive disorder, bipolar disorder, and schizophrenia has greatly increased with the identification of particular genetic variations linked to these conditions [1].

Numerous genetic loci connected to psychiatric disorders have been found thanks to advancements in genome-wide association studies (GWAS) [2]. These results indicate possible routes and molecular targets for therapeutic development in addition to illuminating the polygenic character of these illnesses [3]. For example, the discovery of particular genetic variants in signaling pathways or neurotransmitter receptors has prompted the investigation of focused therapies meant to alter these pathways [4].

In addition, the idea of polygenic risk scores (PRS) has gained popularity. With PRS, an individual's genetic susceptibility is evaluated by computing the cumulative effect of numerous genetic variations linked to psychiatric

diseases [5]. This methodology facilitates the division of patient groups according to their genetic susceptibility, opening the door to customized therapeutic approaches [6].

Though genetic marker discovery offers a potential path toward precision medicine, a number of obstacles still need to be overcome. The interpretation and practical relevance of these findings are further complicated by the intricate interactions among many genetic variations, environmental variables, and gene-environment interactions [7]. Furthermore, to guarantee the robustness and generalizability of discovered genetic markers in many ethnic groups and communities, extensive replication studies and multiple population validations are essential [8].

Essentially, the investigation of genetic markers in mental illnesses has revealed the genetic makeup of these ailments and has the potential to direct the development of focused medications and individualized treatment plans. It is still essential to overcome obstacles in the areas of clinical translation, validation, and interpretation of these genetic discoveries if they are to be successfully incorporated into standard mental health treatment.

Pharmacogenomics and Biomarkers

Pharmacogenomics and biomarkers are essential to the goal of precision medicine in the creation of mental medications. These instruments provide information about individual differences in drug response, which helps to tailor treatment strategies.

Psychiatric Disorder Biomarkers

The term "biomarkers" refers to a broad category of indications that provide details about the biological mechanisms behind mental disorders. These indicators include genetic and molecular markers, neuroimaging, and physiological assessments [1]. For example, brain structure and function can be visualized and quantified using neuroimaging techniques such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI), which make it possible to identify aberrations linked to various psychiatric disorders [2].

Peripheral biomarkers, including inflammatory cytokines or blood-based molecular markers, have also been studied for their ability to guide individualized interventions, predict therapy response, and indicate the severity of a disease [3]. Finding trustworthy and clinically significant biomarkers could be beneficial for early diagnosis, prognosis, and therapy efficacy monitoring in mental health patients [4].

Pharmacogenomics and Customized Medical Interventions

One important aspect of precision psychiatry is pharmacogenomics, which investigates the impact of genetic variants on a person's reaction to psychiatric drugs [5]. Drug metabolism, efficacy, and side effects are greatly impacted by genetic variations in neurotransmitter receptors, transporters, and enzymes that metabolize drugs [6].

For example, differences in the genes that encode cytochrome P450 enzymes (CYP450) can change how commonly prescribed psychiatric drugs, such as antipsychotics and selective serotonin reuptake inhibitors (SSRIs), are metabolized, which can have an impact on their effectiveness and tolerability [7]. Clinicians can tailor dosage schedules or choose different drugs based on their understanding of these genetic variants, which can maximize therapeutic success while reducing side effects [8].

Furthermore, the establishment of guidelines and recommendations for the use of pharmacogenomic testing in clinical practice has been made possible by initiatives such as the Pharmacogenomics Research Network (PGRN) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) [9]. These recommendations help medical professionals understand the findings of genetic testing and decide on the best course of action for each patient based on their unique profile [10].

Obstacles and Prospects for the Future

Though biomarkers and pharmacogenomics hold great promise for transforming mental health treatment, a number of obstacles still need to be addressed. Large-scale longitudinal studies are necessary for biomarker development and validation in order to demonstrate strong correlations and practical applications. Logistical and regulatory hurdles arise when standardizing biomarker testing and integrating them into standard clinical practice [11].

Similar to this, there are obstacles to the broad use of pharmacogenomic testing, including those pertaining to affordability, accessibility, and the preparedness of the healthcare system for genomic medicine [12]. It's also necessary to address ethical issues with patient privacy, informed permission, and the usage of genetic data [13]. In order to uncover full disease signals, future initiatives in biomarker research will integrate multi-omics data and combine transcriptomic, proteomic, genomic, and epigenetic data to improve diagnostic and prognostic tools [14]. Furthermore, developments in machine learning and artificial intelligence may make it possible to analyze large, complicated biomarker data sets and more accurately forecast treatment outcomes [15].

Pharmacogenomics and biomarkers are essential components of precision psychiatry. Their use presents chances for more individualized treatment plans and better patient results. To fully realize their potential and incorporate them into regular psychiatric treatment, it is imperative to tackle issues pertaining to validation, standardization, and ethical considerations.

Precision Psychiatry Using Omics Technologies

A paradigm change in psychiatric research has been sparked by omics technologies, which include proteomics, metabolomics, transcriptomics, and genomes. These technologies provide detailed insights into the molecular landscape that underlies mental health diseases.

Genetics and Mental Illnesses

Uncovering the genetic makeup of mental illnesses has been greatly aided by genomic research. Many genetic variations have been linked to disorders like schizophrenia, bipolar disorder, and major depressive disorder by means of genome-wide association studies (GWAS) [1]. These results clarify the polygenic character of these illnesses by linking several genetic loci to the vulnerability to disease [2].

Moreover, the development of sequencing technologies, including exome and whole-genome sequencing, has made it easier to identify uncommon variations that may have an impact on psychiatric traits [3]. Understanding gene expression patterns and regulatory mechanisms through the integration of genetic results with functional genomics provides insights into the molecular processes implicated in the etiology of illness [4].

Bioinformatics and Molecular Identification

Transcriptome research offers a dynamic perspective on the molecular changes underlying psychiatric diseases by examining gene expression profiles in various circumstances. The identification of genes with variable expression, alternative splicing events, and non-coding RNA dysregulation linked to psychiatric disorders is made possible by RNA sequencing (RNA-seq) approaches [5].

Furthermore, the discovery of molecular signatures or gene expression patterns particular to various psychiatric subtypes or treatment response profiles has been made possible by transcriptome analysis [6]. These fingerprints provide prospective biomarkers for the stratification of diseases and could direct the creation of focused therapies.

Proteomics and Networks of Biomolecules

The investigation of protein expression, post-translational changes, and protein-protein interactions connected to mental illnesses is the focus of proteomic techniques. Protein profiles and dysregulated pathways linked to particular mental disorders can be identified using approaches based on mass spectrometry [7].

In the context of psychiatric disease, the integration of proteomic data with other omics layers facilitates the construction of biomolecular networks and clarifies the interactions between genetic variations, changes in gene expression, and protein modifications [8]. These networks provide a systems-level comprehension of possible therapeutic targets and illness causes.

Biochemistry and Functional Outcomes

With an emphasis on small molecule metabolites in biological systems, metabolomics offers functional readouts of cellular processes that are disrupted in mental illnesses. Metabolomic techniques based on mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy allow the profiling of metabolite signatures linked to disease states or treatment outcomes [9].

Numerous psychiatric disorders have been linked to changes in neurotransmitter pathways, energy metabolism, and inflammatory processes, according to metabolic research [10]. It may be possible to create diagnostic markers and track the effectiveness of treatments by identifying particular metabolite signatures associated with disease subtypes or treatment results.

Obstacles and Prospects for the Future

Omics technologies provide promise for precision psychiatry, but there are still obstacles to overcome. Robust data integration approaches and powerful bioinformatics tools are necessary to overcome the computational and analytical obstacles associated with integrating multi-omics data [11]. Furthermore, to ensure the validity and consistency of omics results in psychiatric research, replication studies, quality control procedures, and standardised methodologies are required [12].

In order to uncover convergent molecular markers across several omics layers and to outline entire disease pathways, future directions entail the integration of multi-omics data. Improvements in machine learning and network-based techniques should help interpret complicated omics data and more accurately forecast treatment response [13].

Omics technologies provide a comprehensive grasp of the molecular causes of mental illnesses. It may be possible to find biomarkers, guide customized interventions, and understand disease mechanisms by combining data from genetics, transcriptomics, proteomics, and metabolomics. In order to transform these developments into therapeutically useful tools for precision psychiatry, it will be essential to address technological and analytical issues.

Targeted Therapies and Drug Development

The pursuit of targeted medicines to target the particular biological pathways linked to psychiatric diseases has been accelerated by the precision psychiatry paradigm. These novel strategies have the potential to reduce side effects and enhance treatment outcomes.

Knowing the Mechanisms of Disease to Implement Targeted Interventions

The complex disease pathways and biological targets underlying psychiatric diseases have been clarified by advances in omics technologies and molecular investigations. Aiming to modify particular molecular processes linked to these disorders, targeted therapies have been made possible by this increased understanding [1].

For example, the discovery that many mental diseases are associated with dysregulated neurotransmitter systems or synaptic pathways has prompted the creation of medications that specifically target these circuits [2]. In order to reduce symptoms and enhance patient outcomes, these targeted medicines seek to modify receptor activation, normalize neurotransmitter levels, or restore synaptic function.

Methods of Treatment Guided by Biomarkers

A cornerstone of precision psychiatry is the use of biomarkers to direct targeted therapy. Biomarkers help in patient categorization and treatment selection based on individual features. They might be genetic markers, neuroimaging patterns, or molecular profiles [3].

The identification of patient subgroups likely to react to particular tailored interventions is made possible by biomarker-driven techniques. For example, genetic markers linked to treatment response or pharmaceutical side effects can help doctors customize treatment plans and reduce trial-and-error when choosing medications [4].

Customized Clinical Studies and Medication Approval

The field of psychiatry's drug development and clinical trial landscape has been impacted by the emergence of precision medicine. Conventional clinical trial designs frequently encompass diverse patient populations, which may obscure treatment effects unique to particular subgroups. To enable more focused and effective studies, precision psychiatry promotes the use of biomarker-driven subgroups in clinical trials [5].

Moreover, regulatory agencies have recognized the significance of customized medicine in the process of approving new drugs. The FDA's "Drug-Diagnostic Co-Development Concept Paper" is one example of an initiative that promotes the concurrent development of companion diagnostics to direct the use of targeted medicines [6]. The goal of this comprehensive strategy is to identify the patient populations most likely to benefit from targeted medicines, hence accelerating their approval.

Difficulties with Accessibility and Implementation

Although targeted medicines have great potential, a number of obstacles prevent them from being widely used in clinical practice. Pharmaceutical companies encounter financial difficulties in developing tailored medications, particularly those intended for smaller patient groupings [7]. Ensuring that these cutting-edge medicines are affordable and accessible to a wide range of patient populations is still a major challenge.

Furthermore, further study and monitoring are required due to issues with treatment resistance, variability in treatment response even within subgroups characterized by biomarkers, and the long-term efficacy and safety profiles of targeted therapies [8]. Implementing these treatments is made more difficult by ethical concerns about fair access to them and possible stigmatization due to genetic or biomarker information.

Prospective Courses and Joint Ventures

Prospective initiatives in targeted therapies and medication development for psychiatric diseases will require cooperation between investigators, practitioners, pharmaceutical companies, and government agencies. The potential to optimize drug design and anticipate treatment responses based on intricate molecular data is presented by developments in computer modeling, artificial intelligence, and machine learning [9].

Moreover, programs encouraging data exchange and cooperative research across institutions and nations are crucial for combining resources and data to expedite the discovery of new drugs and the validation of focused interventions [10]. Precision psychiatry will advance primarily through interdisciplinary collaborations and translational research that connects findings in basic science with therapeutic applications.

Precision medicine techniques and targeted therapies enable a paradigm change in the development of psychiatric drugs by emphasizing customized interventions based on unique biological profiles. Even though accessibility and implementation present obstacles, joint efforts and creative thinking can help realize the potential of focused treatments to improve outcomes for people with psychiatric diseases.

Prospects and Difficulties for the Future

As precision psychiatry develops and strives to transform the identification and management of mental illnesses, it offers both noteworthy opportunities and formidable obstacles.

Progress in Tailored Medical Interventions

Precision psychiatry's future looks bright for more developments in individualized care based on patient characteristics. New approaches and technologies, such as multi-modal imaging, spatial transcriptomics, and single-cell sequencing, have the potential to provide never-before-seen details about the changes in the brain and cells that underlie mental illnesses [1].

Finding novel therapeutic targets and biomarkers for targeted therapies may result from the integration of multi-omics data and the creation of thorough disease signatures. Furthermore, new developments in digital therapeutics provide creative ways to support conventional treatments by utilizing wearable technology and mobile health apps for real-time monitoring and intervention delivery [2].

Taking Care of Implementation Issues

But there are still a lot of obstacles to overcome before these developments may be widely applied in clinical practice. One major obstacle that still needs to be overcome is standardizing data collection, processing, and interpretation procedures across many omics platforms. Important milestones include reaching agreement on biomarker validation, clinical value, and developing protocols for integrating them into clinical decision-making procedures [3].

Furthermore, in the big data era, protecting patient privacy and using sensitive genetic information have ethical ramifications that cannot be overstated. Maintaining a continuous ethical dialogue and developing regulatory frameworks will be necessary to strike a compromise between optimizing the advantages of precision psychiatry and protecting patient autonomy and confidentiality [4].

Overcoming Heterogeneity and Treatment Resistance

Treating treatment resistance and individual differences in response to treatment provide a significant issue in psychiatric care. Some patients still show resistance to existing procedures, even with advances in customized treatments. Developing solutions to get beyond these obstacles requires an understanding of the mechanisms causing treatment resistance, including genetic, epigenetic, and environmental variables [5].

Moreover, finding consistent treatment modalities is difficult due to the intrinsic variability of mental illnesses. A sophisticated strategy is required for individualized therapies due to the range of symptom presentations and underlying pathology. Biological markers and clinical traits may help to subtype patients, which could help with more effective therapy planning. [6].

Initiatives for Collaborative Research and Data Sharing

Initiatives for cooperation and data sharing are essential to the advancement of precision psychiatry. Important initiatives include forming consortia for multi-site investigations, encouraging interdisciplinary partnerships involving geneticists, neuroscientists, physicians, and computational biologists, and supporting open-access repositories for omics data [7].

Furthermore, comprehending the variation in genetic, environmental, and cultural factors impacting psychiatric diseases requires international collaboration and cross-cultural investigations. These kinds of partnerships make it easier to validate results among many populations and support the creation of solutions that are applicable to all [8].

Accepting Ongoing Innovation and Learning

A culture of ongoing innovation and learning must be adopted if precision psychiatry is to advance. It is crucial to teach omics data integration, computational approaches, and personalized medicine principles to upcoming physicians and researchers. Furthermore, encouraging a culture of continuous learning and technological adaptation guarantees the implementation of state-of-the-art methods in psychiatric treatment [9].

In conclusion, tailored treatments could revolutionize mental health care in the future of precision psychiatry. But to fully realize the promise of precision psychiatry in improving outcomes for people with mental health disorders, we must overcome implementation challenges, address treatment resistance, embrace collaborative research efforts, and cultivate a creative and knowledgeable workforce.

References

1. Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012). Genetic architectures of psychiatric disorders: the emerging picture and its implications. *Nature Reviews Genetics, 13*(8), 537-551. DOI: 10.1038/nrg3240.
2. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. *Nature, 511*(7510), 421-427. DOI: 10.1038/nature13595.
3. Charney, A. W., Ruderfer, D. M., Stahl, E. A., Moran, J. L., Chambert, K., Belliveau, R. A., ... et al. (2017). Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder. *Translational Psychiatry, 7*(1), e993. DOI: 10.1038/tp.2016.260.
4. Arango, C., Díaz-Caneja, C. M., McGorry, P. D., Rapoport, J., Sommer, I. E., Vorstman, J. A., ... et al. (2018). Preventive strategies for mental health. *The Lancet Psychiatry, 5*(7), 591-604. DOI: 10.1016/S2215-0366(18)30057-9.
5. Lee, S. H., Ripke, S., Neale, B. M., Faraone, S. V., Purcell, S. M., Perlis, R. H., ... et al. (2013). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nature Genetics, 45*(9), 984-994. DOI: 10.1038/ng.2711.
6. Peterson, R. E., Cai, N., Bigdeli, T. B., Li, Y., Reimers, M., Nikulova, A., ... et al. (2017). The Genetic Architecture of Major Depressive Disorder in Han Chinese Women. *JAMA Psychiatry, 74*(2), 162-168. DOI: 10.1001/jamapsychiatry.2016.3578.

7. Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., ... et al. (2015). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. *Clinical Pharmacology & Therapeutics, 98*(2), 127-134. DOI: 10.1002/cpt.147.

8. Lee, S. H., DeCandia, T. R., Ripke, S., Yang, J., ... Schizophrenia Psychiatric Genome-Wide Association Study Consortium (PGC-SCZ), ... et al. (2012). Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. *Nature Genetics, 44*(3), 247-250. DOI: 10.1038/ng.1108.

9. Akil, H., Brenner, S., Kandel, E., Kendler, K. S., King, M. C., Scolnick, E., ... et al. (2010). The future of psychiatric research: genomes and neural circuits. *Science, 327*(5973), 1580-1581. DOI: 10.1126/science.1188654.

10. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. (2011). Genome-wide association study identifies five new schizophrenia loci. *Nature Genetics, 43*(10), 969-976. DOI: 10.1038/ng.940.

11. International Schizophrenia Consortium, Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O'Donovan, M. C., ... et al. (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature, 460*(7256), 748-752. DOI: 10.1038/nature08185.

12. Smoller, J. W., Andreassen, O. A., Edenberg, H. J., Faraone, S. V., Glatt, S. J., Kendler, K. S., ... et al. (2019). Psychiatric genetics and the structure of psychopathology. *Molecular Psychiatry, 24*(3), 409-420. DOI: 10.1038/s41380-018-0099-7.

13. Wray, N. R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., ... et al. (2018). Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nature Genetics, 50*(5), 668-681. DOI: 10.1038/s41588-018-0090-3.

14. Psychiatric Genomics Consortium Bipolar Disorder Working Group. (2011). Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nature Genetics, 43*(10), 977-983. DOI: 10.1038/ng.943.

15. Craddock, N., & Sklar, P. (2013). Genetics of bipolar disorder. *The Lancet, 381*(9878), 1654-1662. DOI: 10.1016/S0140-6736(13)60855-7.